Bristol Myers Squibb Reports Strong First-Quarter Sales Growth, Primarily from Legacy Products
Bristol Myers Squibb (BMY) reported first-quarter sales growth that exceeded Wall Street expectations, driven mainly by its legacy products. The company's blood thinner Eliquis saw a 16% sales increase to $4.14 billion, surpassing forecasts. However, the growth portfolio underperformed, raising concerns about future performance.
Tickers: $BMY
Topics: Bristol Myers Squibb earnings beat Eliquis pharmaceutical sales stock price movement